Wanbury Limited

BSE: WANBURY524212ISIN INE107F01022

Healthcare
Pharmaceuticals
BSE Healthcare

BSE listing

Share price

₹223.15+0.30 (+0.13%)

as of 18 Sep 2026

52W high: ₹360.00
52W low: ₹162.00
Off 52W high: -38.01%
1M return: -17.20%
3M return: -16.30%
6M return: -9.75%
1Y return: -13.91%
20D avg volume: 12,463
50 DMA: ₹275.88
200 DMA: ₹255.76

Key ratios Consolidated

Market cap: ₹780.29 Cr
Current price: ₹223.15
52W high / low: ₹360.00 / ₹162.00
Face value: ₹10.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: 27.80%
Operating margin: —
Net margin: —
Debt / equity: 2.92
Net debt: ₹169.17 Cr
Interest cover: 1.80
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 8.1 days

Financials

Metric	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	163.18	172.00	—
	0.35	1.84	—
	149.93	154.79	—
	72.78	75.95	—
	3.10	3.89	—
	28.69	26.42	—
	7.54	9.04	—
	3.64	3.37	—
	34.71	31.63	—
	13.61	19.05	—
	0.00	0.00	—
	13.61	19.05	—
	0.12	-1.20	—
	13.49	20.26	—
	4.12	6.18	—
Key metrics
	24.79	31.46	—
	15.20%	18.30%	—
	8.30%	11.80%	—
	—	11.70%	—

Metric	FY25	FY24
Income statement
	599.51	—
	3.49	—
	573.46	—
	277.88	—
	15.08	—
	104.24	—
	36.95	—
	13.31	—
	124.49	—
	29.55	—
	0.00	—
	29.55	—
	-0.98	—
	30.53	—
	9.32	—
Key metrics
	79.81	—
	13.30%	—
	5.10%	—
	27.80%	—
	-22.93	—
	0.85	—
	2.92	—
	169.17	—
	8.1	—
Balance sheet
	413.92	—
	193.44	—
	4.06	—
	114.16	—
	37.68	—
	26.54	—
	189.69	—
	138.46	—
	174.61	—
	173.23	—
	12.94	—
	160.29	—
	59.27	—
Cash flow
	26.10	—
	-51.17	—
	25.73	—
	49.03	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q4 FY24
Income statement
	165.58	164.58	162.45	160.06	163.18	172.00	—
	0.36	0.21	0.18	0.20	0.35	1.84	—
	161.36	146.01	146.76	145.10	149.93	154.79	—
	73.97	62.95	66.51	70.66	72.78	75.95	—
	2.68	2.82	6.06	4.64	3.10	3.89	—
	35.38	29.68	31.84	29.43	28.69	26.42	—
	7.97	8.06	7.26	7.12	7.54	9.04	—
	4.04	3.23	3.74	3.70	3.64	3.37	—
	34.97	39.74	35.13	37.79	34.71	31.63	—
	4.59	18.77	15.87	15.16	13.61	19.05	—
	0.00	-3.60	0.00	0.00	0.00	0.00	—
	4.59	15.17	15.87	15.16	13.61	19.05	—
	1.34	-6.53	0.11	-0.02	0.12	-1.20	—
	3.24	21.70	15.76	15.18	13.49	20.26	—
	0.93	7.33	4.52	4.58	4.12	6.18	—
Key metrics
	16.60	26.46	26.87	25.98	24.79	31.46	—
	10.00%	16.10%	16.50%	16.20%	15.20%	18.30%	—
	2.00%	13.20%	9.70%	9.50%	8.30%	11.80%	—
	—	7.30%	—	8.20%	—	11.70%	—
	1.50%	-4.30%	—	—	—	—	—
	-76.00%	7.10%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	652.67	650.27	599.51	—
	0.95	0.94	3.49	—
	599.23	587.80	573.46	—
	274.09	272.90	277.88	—
	16.20	16.62	15.08	—
	126.33	119.64	104.24	—
	30.41	29.98	36.95	—
	14.71	14.31	13.31	—
	147.63	147.37	124.49	—
	54.39	63.41	29.55	—
	-3.60	-3.60	0.00	—
	50.79	59.80	29.55	—
	-5.10	-6.33	-0.98	—
	55.88	66.13	30.53	—
	17.36	20.55	9.32	—
Key metrics
	95.91	104.09	79.81	—
	14.70%	16.00%	13.30%	—
	8.56%	10.20%	5.10%	—
	—	28.40%	27.80%	—
	—	8.50%	—	—
	—	116.60%	—	—
	—	-27.53	-22.93	—
	—	0.48	0.85	—
	—	1.49	2.92	—
	—	213.84	169.17	—
	—	48.6	8.1	—
Balance sheet
	—	517.67	413.92	—
	—	238.56	193.44	—
	—	1.61	4.06	—
	—	143.28	114.16	—
	—	50.63	37.68	—
	—	34.32	26.54	—
	—	226.51	189.69	—
	—	107.25	138.46	—
	—	201.04	174.61	—
	—	215.45	173.23	—
	—	68.30	12.94	—
	—	147.15	160.29	—
	—	144.45	59.27	—
Cash flow
	—	31.53	26.10	—
	—	-56.40	-51.17	—
	—	22.42	25.73	—
	—	59.06	49.03	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 43.01%

Holder	Type	Holding	Previous	Change
EXPERT CHEMICALS (INDIA) PVT LTD	Promoter	34.36%	—	—
KINGSBURY INVESTMENTS INC	Promoter Group	8.65%	—	—
SURESH BHATIA	Public	3.11%	—	—
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	2.07%	—	—
ZAKI ABBAS NASSER	Public	1.76%	—	—
SHARMIN NASSER	Public	1.33%	—	—
BASAVA SANKARARAO KOLLI	Public	1.16%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.2 Sep 2026 · Company Update / Newspaper Publication
The register of members and share transfer books of the Company will remain closed from Friday, 18 September, 2026 to Thursday, 24 September, 2026 (both days inclusive) for the purpose ....31 Aug 2026 · Corp. Action / Book Closure
Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.31 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).31 Aug 2026 · AGM/EGM / AGM
Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11.30 A.M.28 Aug 2026 · Company Update / Newspaper Publication
Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.13 Aug 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting held on August 11, 202611 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Press Release on Un-audited Financial Results for the quarter ended 30th June, 202611 Aug 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting held on August 11, 202611 Aug 2026 · Company Update / Change in Management
Financial Results for the first quarter ended 30th June, 202611 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting held on August 11, 202611 Aug 2026 · Board Meeting / Outcome of Board Meeting
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....3 Aug 2026 · Board Meeting / Board Meeting
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs30 Jul 2026 · Company Update / Press Release / Media Release
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company''s Facilty.22 Jul 2026 · Company Update / General
A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company''s facility at Tanuku, West Godavari District, ....20 Jul 2026 · Company Update / General
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent ....17 Jul 2026 · Company Update / General
The Exchange has sought clarification from Wanbury Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....16 Jul 2026 · Company Update / Clarification
Resolution passed through circulation by the Board of Directors of the Company regarding early redemption in full of 12.5% secured, guaranteed, senior, taxable, non-cumulative, unrated, ....15 Jul 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd13 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd9 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd9 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Investor Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March, 2026 and is also available on the website of the Company at www.wanbury.com1 Jul 2026 · Company Update / Investor Presentation
Outcome of the Board Meeting - Change in Management26 Jun 2026 · Company Update / Change in Management
Outcome of the Board Meeting dated 26.06.202626 Jun 2026 · Others / Outcome without intimation
Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Press Release dated 25.06.2026 titled Intimation of pledge being released on equity shares held by the Promoter Group and reduction in rate of interest from 12.5% per annum to Sub 10% per annum.25 Jun 2026 · Company Update / Press Release / Media Release
Press Release on Quality inspection by the Therapeutic Goods Administration (TGA) at Tanuku, Andhra Pradesh10 Jun 2026 · Company Update / Press Release / Media Release
Press Release on Launch of New APIs.9 Jun 2026 · Company Update / Press Release / Media Release
Pursuant to Regulation 30 (6) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, we wish to inform you that the Company is organizing a plant visit and management meeting ....2 Jun 2026 · Company Update / Analyst / Investor Meet
Press Release on Q4 & Year ended FY 2026 for Audited Financial Results2 Jun 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting held on 29.05.202629 May 2026 · Result / Financial Results
Outcome of the Board Meeting held on 29.05.202629 May 2026 · Board Meeting / Outcome of Board Meeting
The Board Meeting to be held on 14/05/2026 has been revised to 29/05/2026 The Board Meeting to be held on 14/05/2026 has been revised to 29/05/202612 May 2026 · Company Update / Board Meeting Rescheduled
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....5 May 2026 · Board Meeting / Board Meeting
Press Release on MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection.28 Apr 2026 · Company Update / Press Release / Media Release
Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2026.24 Apr 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....8 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 20186 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Trading Window Closure for the last quarter and year ended 31st March, 2026.26 Mar 2026 · Insider Trading / SAST / Closure of Trading Window

Corporate actions

Purpose	Ex date	Record date	Payment date
E.G.M.	13 Feb 2025	—	—

Board meetings

11 Aug 2026 Board Meeting - Financial Results